(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced a commercial partnership with ClearCardio (TM), a leading preventive ...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...
HeartBeam Inc. (NASDAQ:BEAT) saw its stock soar 52.6% in premarket trading Wednesday after the company announced that the FDA has granted 510(k) clearance for its 12-lead electrocardiogram (ECG) ...
HeartBeam Recently Received US Food and Drug Administration (FDA) Clearance for First-Ever Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment Pivotal Milestone Unlocks Multiple Key ...
(RTTNews) - HeartBeam, Inc. (BEAT), a medical technology company, announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company's groundbreaking ...
FDA Clearance Granted After Successful Appeal, Overturning Prior Not Substantially Equivalent (NSE) Outcome HeartBeam’s Credit-Card Sized Device Delivers Clinical-Grade Insights Directly to Patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results